NCT01860287View on ClinicalTrials.gov

The Effects of Buprenorphine on Responses to Verbal Tasks

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Basic Science
Interventions
DRUG

Buprenorphine 0.2 MG Sublingual Tablet

This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.2)

DRUG

Placebo

This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive a placebo

DRUG

Buprenorphine 0.4 MG Sublingual Tablet

This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.4)

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT01860287 - The Effects of Buprenorphine on Responses to Verbal Tasks | Biotech Hunter | Biotech Hunter